Species |
Human |
Protein Construction |
Mature TGF beta 3 (Ala301-Ser412) Accession # P10600-1 |
Avi |
N-term |
C-term |
|
Conjugate |
Biotin |
Purity |
> 95% as determined by Bis-Tris PAGE |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human TGFbeta RII, mFc Tag at 1μg/ml (100μl/well) on the plate can bind Mature TGF beta 3[Biotin], Avi, Human. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
14.53 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 15-20 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in 4mM HCl. |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 4mM HCl. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
Transforming growth factor-beta 3 is a cytokine which is involved in cell growth regulation and differentiation, stimulation of extracellular matrix and modulation of immune responses. TGF beta 3 RNA is expressed in a diverse array of tissues including perichondrium, bone, intervertebral discs, mesenteries, pleura, heart, lung, palate, and amnion, as well as in central nervous system (CNS) structures such as the meninges, choroid plexus and the olfactory bulbs. Furthermore, in several organ systems, TGF beta 3 transcripts are expressed during periods of active morphogenesis suggesting that the protein may be an important factor for the growth and differentiation of many embryonic tissues. |
Synonyms |
TGF-beta-3; LAP; TGFB3; ARVD; ARVD1; RNHF;TGF-β-3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.